Pancreatic cancer is not one disease but a collection of subtypes that look different under the microscope, behave differently, and respond differently to treatment. Genetic mutations like KRAS and TP53 drive initial tumor development, but they do not explain the full range of pancreatic cancer's diverse biology. Epigenetics — chemical modifications to DNA and proteins that control which genes are switched on or off without changing the DNA sequence itself — plays a critical role.
Epigenetic modifications are particularly interesting because, unlike genetic mutations, they are reversible. This makes them potential targets for new drugs. However, to develop targeted epigenetic therapies, researchers first need to map which modifications are present in which cancer subtypes — something this study set out to do systematically.
The researchers developed a novel spatial epigenomics technique combining Raman hyperspectral mapping (RHM) with convolutional neural networks (CNNs). Raman spectroscopy shines laser light on tissue and analyzes the scattered light to produce a chemical fingerprint — different molecular modifications produce different spectral signatures.
Using an autoencoder neural network to process the high-dimensional spectral data, the team could identify and semi-quantify specific epigenetic marks — DNA methylation, histone methylation, and histone acetylation — across different regions of the same tissue section. The CNN classified these signals automatically, enabling systematic comparison across six pancreatic cancer subtypes and benign control tissue.
Six pancreatic cancer subtypes were analyzed: conventional ductal adenocarcinoma (cPDAC), adenocarcinoma from intraductal papillary mucinous neoplasm (IPMC), predominantly large-duct type, foamy-gland/clear-cell type (FG), squamous differentiated type (SD), and ampulla of Vater adenocarcinoma (AVAC). The results showed significant variation in epigenetic modification levels between subtypes.
The foamy-gland and squamous-differentiated subtypes had markedly elevated global levels of epigenetic modifications and higher ratios of Z-DNA — an unusual left-handed form of DNA associated with active gene regulation and immune signaling. In contrast, the conventional ductal subtype showed more moderate epigenetic activity.
Elevated Z-DNA is associated with activation of immune-related pathways (via proteins like ZBP1 and ADAR1), suggesting these subtypes may have distinct immunological microenvironments. This could explain why they respond differently to immunotherapy.
The high epigenetic modification levels in foamy-gland and squamous-differentiated subtypes suggest these tumors may already have maximally active epigenetic programs that are less responsive to drugs designed to block specific epigenetic regulators (like HDAC inhibitors or methylation inhibitors). Adding more epigenetic activity on top of an already active baseline may have limited effect.
By contrast, conventional ductal pancreatic cancer — the most common subtype — emerged as the most promising candidate for treatment with epigenetic modulators. The moderate baseline epigenetic activity in this subtype offers more room for therapeutic intervention.
This kind of subtype-specific insight is exactly what precision oncology aims to achieve: moving away from one-size-fits-all treatment toward therapies matched to the biology of each individual patient's tumor.
This study introduces a powerful new methodology — spatially resolved epigenomics with AI-assisted spectral analysis — that can characterize the epigenetic landscape of individual tumor biopsies at subtype resolution. This could eventually guide treatment selection in clinical practice.
Future work will need to correlate these epigenetic profiles with patient outcomes and drug responses in prospective clinical studies. If confirmed, this approach could make subtype-specific epigenetic therapy a reality for pancreatic cancer patients.